Stockscreener 앱 받기
3.35
4.04%
0.13
시간 외 거래:
3.35
전일 마감가:
$3.22
열려 있는:
$3.17
하루 거래량:
548.38K
Relative Volume:
1.52
시가총액:
$128.36M
수익:
$1.50M
순이익/손실:
$-81.41M
주가수익비율:
-0.695
EPS:
-4.82
순현금흐름:
$-43.75M
1주 성능:
+13.56%
1개월 성능:
+20.07%
6개월 성능:
+83.06%
1년 성능:
-25.22%
1일 변동 폭
$3.13
$3.36
1주일 범위
$2.72
$3.36
52주 변동 폭
$1.68
$4.79
립 테라퓨틱스 Stock (LPTX) Company Profile
명칭
Leap Therapeutics Inc
전화
617 252 4343
주소
47 THORNDIKE STREET, CAMBRIDGE, MA
LPTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
3.35 | 128.36M | 1.50M | -81.41M | -43.75M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
립 테라퓨틱스 Stock (LPTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-10-04 | 개시 | Mizuho | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2019-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-09-13 | 재개 | Raymond James | Outperform |
| 2017-03-07 | 개시 | Ladenburg Thalmann | Buy |
모두보기
립 테라퓨틱스 주식(LPTX)의 최신 뉴스
Gastric Cancer Pipeline, Treatment Drugs, Clinical Trials and Companies 2024 (Updated) - openPR
Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Up 50.7% in December - MarketBeat
HighTower Advisors LLC Makes New $65,000 Investment in Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Candel Therapeutics Shares Leap on Chairman Purchase - MarketWatch
Biliary Tract Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight - EIN News
Tonix stock jumps on FDA review for pain drug (TNXP:NASDAQ) - Seeking Alpha
Tenaya stock in selloff on gene therapy data (TNYA:NASDAQ) - Seeking Alpha
Neural Therapeutics Announces Changes to Board of Directors and Completion of Debt Settlement - Yahoo Finance
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap - Investing.com Australia
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap By Investing.com - Investing.com South Africa
LEAP-012 Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma - The ASCO Post
Leap Therapeutics CEO to Present at Piper Sandler Healthcare Conference | LPTX Stock News - StockTitan
HC Wainwright Reaffirms Buy Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World
Microsoft's Azure Chips Promise AI Leap, Taking on Nvidia and AMD in Cloud Tech Race - Yahoo Finance
HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310% - BP Journal
Simplify Asset Management Inc. Acquires 425,626 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Balyasny Asset Management L.P. Reduces Stake in Leap Therapeutics Inc - GuruFocus.com
Leap Therapeutics Reports Third Quarter 2024 Financial Results - citybiz
Leap Therapeutics Reports Wider Q3 Loss, Advances Cancer Drug Trials with $62.8M Cash | LPTX Stock News - StockTitan
Liquor, Wine, Beer: Which Comes With the Worst Lifestyle? - 69News WFMZ-TV
Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales - FiercePharma
Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, - GlobeNewswire
DKN-01 With Tislelizumab and Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - The ASCO Post
Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Payment processor Finix secures $75m in Series C funding - Electronic Payments International
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases - Business Wire
FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug - pharmaphorum
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy - FiercePharma
Dow Jones notches new record, chip stocks leap higher - Yahoo Finance
Marshall Wace LLP Acquires New Stake in ChromaDex Co. (NASDAQ:CDXC) - Defense World
Profire Energy, Inc. (NASDAQ:PFIE) Shares Sold by Marshall Wace LLP - Defense World
Marshall Wace LLP Makes New Investment in Vivid Seats Inc. (NASDAQ:SEAT) - Defense World
SoFi's $2 Billion Leap: Golden Cross Sparks A Bullish Boom - Yahoo Finance
Startup company founded by Washington University scientists acquired by Eli Lilly – WashU Medicine - WashU Medicine
Venous Leg Ulcers Treatment Market value, Innovations Driving Market Evolution (2024-2036) - Third Eye News
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients - The Malaysian Reserve
LPTXLeap Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Venous Leg Ulcers Treatment Market Growth, Size, Research Report and Forecast (2024-2034) - Talented India
Leap Therapeutics (NASDAQ:LPTX) Share Price Passes Below 50 Day Moving Average of $2.58 - MarketBeat
Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals - openPR
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Alphamin Resources Corp. (CVE:AFM) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Simplify Asset Management Inc. Has $1.24 Million Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Simplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Meiji Yasuda Asset Management Co Ltd. Has $1.22 Million Stock Position in Hilton Worldwide Holdings Inc. (NYSE:HLT) - Defense World
Commonwealth Equity Services LLC Boosts Position in AllianzIM U.S. Large Cap Buffer10 Sep ETF (NYSEARCA:SEPT) - Defense World
Newmark Security (LON:NWT) Stock Price Crosses Above Two Hundred Day Moving Average of $91.75 - Defense World
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
립 테라퓨틱스 (LPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.60%
2.24%
자본화:
|
볼륨(24시간):